Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world Evidence on Semaglutide in Type 2 Diabetes Mellitus with End-stage Renal Disease
ChiCTR2600117256Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) and end-stage kidney disease (ESKD) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Change in HbA1c at 3 months. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ChiCTR2600117256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117256.